Trial Profile
Phase I/II clinical trial: Immunotherapy of prostate cancer patients in biochemical relapse with dendritic cell-based vaccine
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Dec 2018
Price :
$35
*
At a glance
- Drugs Stapuldencel-T (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 26 Jun 2014 The status has been changed from recruiting to discontinued according to the European Clinical Trials database.
- 29 May 2014 According to a SOTIO media release, results from this trial will be presented at the 2014 American Society of Clinical Oncology Annual Meeting.
- 29 Mar 2012 Planned number of patients changed from 15 to 30 as reported by European Clinical Trials Database record.